Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Osimertinib + RMC-4630|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 21||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EFGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EFGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|RMC-4630||RMC-4630-02|SAR442720|SAR 442720||SHP2 Inhibitor 13||RMC-4630 is an inhibitor of SHP2 (PTPN11) that prevents MAPK signaling and cell growth (PMID: 31727671).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03989115||Phase Ib/II||Cobimetinib + RMC-4630 Osimertinib + RMC-4630||Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC||Recruiting||USA||1|